Walgreens' March sales rise 4.5% year-over-year to US$6.43B as sales in comparable stores rose 3.5%; for first three months of 2013, sales are up 4.3% to US$18.86B

DEERFIELD, Illinois , April 3, 2014 (press release) –

Walgreens (WAG) (WAG) had March sales of $6.43 billion, an increase of 4.5 percent from $6.16 billion for the same month in fiscal 2013.

With Easter falling on April 20 this year compared with March 31 last year, total front-end sales decreased 2.6 percent in March compared with the same month in fiscal 2013, while comparable store front-end sales decreased 3.4 percent. Customer traffic in comparable stores decreased 4.0 percent while basket size increased 0.6 percent. Walgreens will report combined comparable store sales for March and April with its April sales results.

Prescriptions filled at comparable stores increased by 5.1 percent in March and increased 4.2 percent on a calendar day-shift adjusted basis. March 2014 had one additional Monday and one fewer Friday compared with March 2013. These calendar shifts positively impacted prescriptions filled at comparable stores by 0.9 percentage point. Prescriptions filled at comparable stores were negatively impacted by 0.3 percentage point due to the lower incidence of flu in March 2014.

March pharmacy sales increased by 8.9 percent. Comparable store pharmacy sales increased 8.0 percent and increased by a calendar day-shift adjusted 7.1 percent. Calendar day shifts positively impacted pharmacy sales in comparable stores by 0.9 percentage point. Calendar day-shift adjusted comparable store pharmacy sales were negatively impacted by 1.6 percentage points due to generic drug introductions in the last 12 months, and were negatively impacted by 0.4 percentage point due to a lower incidence of flu. Pharmacy sales accounted for 64.7 percent of total sales for the month.

Sales in comparable stores increased by 3.5 percent in March. Calendar day shifts positively impacted total comparable sales by 0.6 percent. Generic drug introductions in the last 12 months negatively impacted total comparable sales by 1.0 percentage point, while the lower incidence of flu negatively impacted total comparable sales by 0.2 percentage point.

Calendar 2014 sales were $18.86 billion, an increase of 4.3 percent from $18.09 billion in 2013.

Fiscal 2014 year-to-date sales for the first seven months were $44.39 billion, an increase of 5.4 percent from $42.12 billion in fiscal 2013.

Walgreens opened 13 stores during March, including three relocations, acquired three and closed one.

On March 31, Walgreens operated 8,688 locations in all 50 states, the District of Columbia, Puerto Rico, Guam and the U.S. Virgin Islands. That includes 8,221 drugstores, 144 more than a year ago, including 63 net stores acquired over the last 12 months. The company also operates infusion and respiratory services facilities, specialty pharmacies and mail service facilities. Its Take Care Health Systems subsidiary manages more than 750 in-store convenient care clinics and worksite health and wellness centers.

 
March Comparable Sales and Prescriptions Filled
                         
           

Calendar

         

Cough,

           

Shift

   

Generics

   

Cold, Flu

     

Actual

   

Impact

   

Impact

   

Impact

                         
Total Comp Sales     3.5%     0.6%    

-1.0%

   

-0.2%

Comp Front End     -3.4%     -     -     -
Comp Rx Sales     8.0%     0.9%    

-1.6%

   

-0.4%

Comp Rx Scripts     5.1%*     0.9%     -    

-0.3%

 

* Includes +2.4 percentage points from patients filling more 90-day prescriptions

Please note: Sales numbers and the adjustments shown in the table are preliminary, unaudited and subject to revision. Comparable stores are defined as those drugstore locations open for at least 12 consecutive months without closure for seven or more consecutive days and without a major remodel or a natural disaster in the past 12 months. Acquired operating locations and relocations are not included as comparable stores for the first 12 months after the acquisition or relocation.

Cautionary Note Regarding Forward-Looking Statements: Statements in this release that are not historical are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "expect," “likely,” "outlook," “forecast,” "would," "could," "should," “can,” “will,” "project," "intend," "plan," "goal,” “target,” “continue," "sustain," “synergy,” "on track," "believe," "seek," "estimate," "anticipate," "may," “possible,” "assume," and variations of such words and similar expressions are intended to identify such forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, assumptions and uncertainties, including, but not limited to, those described in Item 1A (Risk Factors) of our most recent Annual Report on Form 10-K, which is incorporated herein by reference, and in other documents that we file or furnish with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Except to the extent required by law, Walgreens does not undertake, and expressly disclaims, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

 

Contact:
Walgreens
Media contact:
Emily Hartwig, 847-315-3316
or
Investor contacts:
Rick Hans, CFA, 847-315-2385
Ashish Kohli, CFA, 847-315-3810
http://news.walgreens.com
@WalgreensNews
facebook.com/Walgreens

© 2019 Business Wire, Inc., All rights reserved.